Bromocriptine protects perilesional spinal cord neurons from lipotoxicity after spinal cord injury

Recent studies have revealed that lipid droplets accumulate in neurons after brain injury and evoke lipotoxicity,damaging the neurons.However,how lipids are metabolized by spinal cord neurons after spinal cord injury remains unclear.Herein,we investigated lipid metabolism by spinal cord neurons after spinal cord injury and identified lipid-lowering compounds to treat spinal cord injury.We found that lipid droplets accumulated in perilesional spinal cord neurons after spinal cord injury in mice.Lipid droplet accumulation could be induced by myelin debris in HT22 cells.Myelin debris degradation by phospholipase led to massive free fatty acid production,which increased lipid droplet synthesis,β-oxidation,and oxidative phosphorylation.Excessive oxidative phosphorylation increased reactive oxygen species generation,which led to increased lipid peroxidation and HT22 cell apoptosis.Bromocriptine was identified as a lipid-lowering compound that inhibited phosphorylation of cytosolic phospholipase A2 by reducing the phosphorylation of extracellular signal-regulated kinases 1/2 in the mitogen-activated protein kinase pathway,thereby inhibiting myelin debris degradation by cytosolic phospholipase A2 and alleviating lipid droplet accumulation in myelin debris-treated HT22 cells.Motor function,lipid droplet accumulation in spinal cord neurons and neuronal survival were all improved in bromocriptine-treated mice after spinal cord injury.The results suggest that bromocriptine can protect neurons from lipotoxic damage after spinal cord injury via the extracellular signal-regulated kinases 1/2-cytosolic phospholipase A2 pathway.

Effect of Chinese Herbs Bu-shen on Expression of Pituitary PRL-R and PrRP-R in the Bromocriptine-induced Hypoprolactin Rat Abortion Model

Objective To study the effect of Chinese herbs preparation Bu-shen on pituitary prolactin-releasing peptide receptor (PrRP-R) and prolactin receptor (PRL-R) expression in the bromocriptine-induced rat abortion model Materials & Methods Female SD rats were divided into five groups randomly. Group A,B,C and D were injected with bromocriptine [0. 3 mg/(kg · d)] during the pregnant day 6～ 8, respectively. Group B was given powder of Bu-shen herbs [3 g/(kg · d)]. Group C was injected with prolactin (8 IU) twice a day and Group D with progesterone [(8 mg/kg · d) in the pregnant day 1～ 11. The rats in Group E were normal pregnant rats. All these rats were killed at the pregnant day 12 to observe the expression of PrRP-R, PRL-R from the pituitary using RT-PCR. Results The pregnant rate and total number of litters in Group A were significantly lower than those in Group B, C, D and E (P＜0. 01) and the expression of PrRP-R and PRL-R in the pituitary of Group A was higher than that of any other group. Conclusion Preparation Bu-shen plays a regulatory role in the secretion of prolactin possibly via modulating rats' hypothalamus and pituitary.

Hormone Secretion by Cell Culture of Human GH-PRL Secreting Pituitary Adenomas: Effects of Bromocriptine

Dopamine agonists effectively reduce the secretion of prolactin (PRL) in the great majority of prolactinomas and reduce the bulk of the adenomas, as well as have partial therapeutic effect on some patients with acromegaly. The inhibitory effect of bromocriptine (BC), a dopamine agonist, on growth hormone (GH) and PRL secretion of dispersed cells from the pituitary adenomas of 16 cases of acromegaly, which secret GH and PRL simultaneously, were evaluated in vitro. The significant inhibitory effects of BC on PRL secretion were found in 12 cases. It was also found that PRL secretion was strongly inhibited when GH was suppressed; on the contrary, when GH secretion was not suppressed, the production of PRL was not or weakly inhibited. The exact mechanism of the effects is nuclear so far. It is necessary to investigate, at molecular level, the etiology of GH-PRL adenomas and its response to therapeutic agents.

Auditory evoked potentials recorded in monkeys with hallucinatory-like behaviors induced by bromocriptine

Objective Bromocriptine and other dopamine D2 receptor agonists can affect a range of behaviors in nonhuman primates, particularly those behaviors associated with motor and mental function, such as suppressant behaviors and hallucinatory-like behaviors in monkeys. Besides bromocriptine, the dysfunction of the rapid eye movement sleep （REM） mechanism may also contribute to hallucinations. Dissociation of wakefulness, REM, and non-REM （NREM） can cause a series of psychotic symptoms. Methods In present study, we simultaneously recorded auditory evoked potentials （AEP） from five cerebral regions in monkeys during normal and psychotomimetic states to investigate and compare state-dependent changes in AEE Results Phase reversal of peak-to-baseline amplitude of 250 ms component （PBA250） in dorsolateral prefrontal cortex was common characteristic of hallucinatory-like and REM, and that hallucinatory-like and REM shared the equivalent modulatory orderliness of the PBA250 in dorsolateral prefrontal cortex. This result suggests that hallucinatory-like and REM share an equivalent electrophysiological modulatory in dorsolateral prefrontal cortex. Conclusion Our results reveal that emergence of the N250 in dorsolateral prefrontal cortex is an exclusive marker that may help to discern whether hallucinatory-like behaviors is exhibited, which suggests that dorsolateral prefrontal cortex may be the most pivotal region for exhibition of hallucinatory-like behaviors.

Synergistic effect of bromocriptine and tumor necrosis factor-a on reversing hepatoceiiuiar carcinoma multidrug resistance in nude mouse MDRl model of liver neoplasm

AIM： To investigate the effect of bromocripUne （BCT） and tumor necrosis factor-α ClNF-α） on hepatocellular carcinoma （HCC） multidrug resistance （MDR） in nude mouse HDR model of liver neoplasm. METHODS： Human hepatocarcinoma cell line HepG2t drug resistant hepatocarcinoma cell line HepG2/adriamycin （ADM） and hepatocarcinoma cell line transfected with TNF-α gene HepG2JADM/TNF were injected into the liver of nude mice via orthotopic implantation and MDR model of liver neoplasm in vivo was established （HepG2t ADM, TNF, BCT groups）. Among these groups, BCT group and TNF group were treated with BCT through gastric canal. Each group was divided into control group and chemotherapy group. Size and weight of the tumor were measured. Furthermore, tumor his^logical character and growth of the nude mice were observed and their chemosensitivity was tested. MDR-associated genes and proteins （MRP, LRP） of implanted tumors were detected by immunohistochemistry, reverse transcriptase polymerase chain reaction, and apoptosis rate of hepatocarcinoma cells was detected by TUNEL assay. RESULTS： The nude mouse model of each cell line was inoculated successfully. The tumor growth rate and weight were significantly different among groups. After chemotherapy, abdominal cavity tumor growth inhibition rate was higher in BCT group （67%） compared to ADM and TNF groups, and similar to HepG2group （54%）. MDRI and LRPmRNA could be detected in all groups, but TNF-α was detected only in TNF and BCT groups. Furthermore, MDR1 and LRP protein expression of tumors in TNF and BCT groups was low similar to HepG2 group. The apoptosis rate of hepatocarcinoma cells was much higher in BCT group than in other groups with TUNEL assay. CONCLUSION： BCT and TNF-a can reverse HCC MDR in nude mouse MDR1 model of liver neoplasm. 2005 The WJG Press and Elsevier Inc. All rights reserved

Bromocriptine in Central Hyperthermia after Severe Traumatic Brain Injury

Strong evidence showed that fever after traumatic brain injury TBI is associated with increased mortality. In this study, we tried to evaluate the role of Bromocriptine in central hyperthermia in patients with severe TBI. This prospective controlled study was conducted on 50 severe TBI patients who admitted to the critical care department and confirmed on Computed Tomography (CT) of the brain and GCS of less than 9 at admission. Then, they were randomly assigned into 2 groups. Bromocriptine group (25) received bromocriptine 7.5 mg/day during 24 hours from admission through a naso-gastric (NG) feeding tube. Control group (25) received conventional treatment only. Temperature was measured every 2 hours. The antipyretic measures used were the same across all patients enrolled. The primary outcome was number of patients diagnosed with central hyperthermia. After the discharge of all patients, there was a statistically significant difference between the 2 groups in number of patients diagnosed with central hyperthermia (6 (24%) in bromocriptine group Vs 18 (72%) in control, p = 0.002). There were no differences in hospital length of stay (p = 0.904) or mortality (p = 0.393). Early administration of bromocriptine in severe TBI may be associated with lower incidence of central hyperthermia with no effect on length of stay or mortality.

Uncontrolled central hyperthermia by standard dose of bromocriptine:A case report

BACKGROUND Some patients present to the intensive care unit due to noninfectious pathologies resulting in fever,especially acute neurological injuries,including brain trauma and intracranial haemorrhage.The cause has been identified to be central hyperthermia characterized by a high core temperature and a poor response to antipyretics and antibiotics.However,no proper guidelines on how to treat central hyperthermia have been developed for clinical practice.CASE SUMMARY A 63-year-old woman was transferred to our hospital due to injury after a traffic accident.Eight hours after admission,her pupils enlarged bilaterally from 2.5 mm to 4.0 mm.She developed severe coma and underwent decompressive craniectomy.She was diagnosed with central hyperthermia after surgery and was prescribed bromocriptine.The standard dose of bromocriptine could not control her hyperpyrexia,and we prescribed 30 mg a day to control her temperature.CONCLUSION Bromocriptine may be effective in controlling central hyperthermia and have a dosage effect.

Sex-related changes in tumor consistency in prolactinoma patients after bromocriptine pretreatment

Objective It has long been reported that prolactinomas treated with bromocriptine increase fibrosis and may affect surgical outcomes.We retrospectively studied 238 consecutive patients with histopathologically confirmed prolactinomas undergoing microsurgery in a single neurosurgery department of Tongji Hospital(Wuhan,China) from 2012 to 2015 in order to evaluate tumor consistency changes after bromocriptine pretreatment and surgical outcomes.Methods We divided the patients into four groups;males in the dopamine agonist(DA) group,females in the DA group,males in the no DA group,and females in the no DA group,and we compared the surgery process,specimen Masson staining,and clinical outcomes of the four groups.According to a previously published classification,the operative notes from an experienced neurosurgeon were reviewed to classify the consistency of tumors as "fibrous" or "nonfibrous".Results No differences in tumor consistency were found in male patients with or without DA treatment.However,in female patients with DA treatment,tumors were likely to be harder in texture than the tumors of female patients without DA treatment.Despite tumor consistency differences between sexes,the tumor biological remission rate was similar between groups,as was the rate of tumor resection.Discussion Our study indicates that preoperative DA therapy impacts tumor consistency in female patients but not male patients.Although the surgical and histopathological outcomes are not influenced,these findings may provide useful information for the choice of operative approach and surgery process for pituitary adenoma.

Bromocriptine enhances the uptake of^(99m)Tc-MIBI in patients with hepatocellular carcinoma

99mTc-methoxyisobutyl isonitrile （MIBI） is a suitable transport substrate for the multidrug resistance gene prod- uct P-glycoprotein （P-gp） and widely used for tumor imaging. Bromocriptine has been shown to inhibit the ATPase activity and the function of P-gp. We hypothesized that bromocriptine could promote the accumulation of MIBI by inhibiting P-gp activities, a feature that can be taken advantage of for enhancing 99mTc-MIBI imaging. In the cur- rent study, we sought to investigate whether bromocriptine enhanced the uptake of 99mTc-MIBI in hepatocellular carcinoma patients. Sixty primary hepatocellular carcinoma patients received 99mTc-MIBI single photon emission computer tomgraphy （SPECT） prior to surgery. 99mTc-MIBI SPECT was performed 15 and 120 min after injec- tion of 20 mCi 99mTc-MIBI, and early uptake, delayed uptake （L/Nd）, and washout rate （L/Nwr） of 99mTc-MIBI were obtained. In addition, a second 99mTc-MIBI SPECT was performed according to the same method 48 h after bromocriptine administration. We found that, prior to bromocriptine administration, significant MIBI uptake in tumor lesions was noted in only 10 （16.7%, 10/60） patients with hepatocellular carcinoma. No significant MIBI uptake was observed in the tumor lesions of the remaining 50 （83.3%, 50/60） hepatocellular carcinoma patients. Following bromocriptine administration, all the patients without apparent MIBI uptake demonstrated significant MIBI uptake on 99mTc-MIBI SPECT （P 〈 0.05）. Our findings indicate that bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma.

Effect of Bromocriptine on Insulin Resistance in Patients with PCO

Introduction: Poly cystic ovary (PCO) is one of the most common endocrine disorders in women. All patients with PCO are at risk of insulin resistance, IFG and diabetes. Recently, bromocriptine is used in treatment of diabetes mellitus type II to improve insulin resistance. Objective: The aim of this study is the evaluation of bromocriptine on insulin resistance in PCO people. Patients and Methods: In this single-blind controlled clinical trial with placebo, 44 patients with PCO referring to endocrinology clinic were evaluated. Inclusion criteria were BMI > 25 kg/m2 and diagnosed PCO patients according to Rotterdam criteria and rule out other causes. Blood samples were obtained for FBS, Fasting Insulin, Prolactin, TSH and 17(OH)P. They divided two groups: Case group was given bromocriptine 2.5 mg daily and placebo was given to control group. Patients were treated for 8 days and in day 9th blood sample was obtained for FBS, Fasting insulin, HOMA-IR index. Mann-Whitney method is used for mean comparison. Results: Data analysis using showed in pre diabetes range, mean changes of FBS, insulin level and IR in Groups 1 and 2 had significant differences(P = 0.004), but no significant different was found in FBS < 100 mg/dl (P = 0.92). In group with BMI 2, no significant differences were found in changes in FBS < insulin level and IR (P = 0.13, 0.13, and 0.11 respectively). In group with BMI ≥ 30 kg/m2, no significant differences were found in changes in insulin level and IR (P = 0.69, 0.089 respectively). Mean systolic blood pressure changes in Group 1 and 2 in FBS > 100 mg/dl with (P = 0.036) were significant, but no significant difference showed in mean change of diastolic blood pressure in FBS > 100 mg/dl (P = 0.99). In FBS < 100 mg/dl mean changes in systolic and diastolic blood pressures were not significant (P = 0.6). Age showed no difference changes in effect on treatment in Groups 1 and 2 (P = 0.1). Conclusion: Our study showed, even in the short-term consumption, bromocriptine reduced FBS and insulin levels and insulin resistance in PCO patients with pre-diabetes range.

Effect of Chinese Herbs Bu-shen on PRLR, PR, ER mRNA of Decidue in Bromocriptine-induced Hypoprolac- tin Rat Abortion Model

Objective To explore the effect of Chinese herbs on PRLR, PR, ER mRNA of decidue in Bromocriptine-induced hypoprolactin abortion rat model from gene transcription level, and observe the changes of blood PRL, P, E2.Methods RT-PCR method was taken to analyses the differences of PRLR, PR, ER mRNA in decidue between model group (A group) and model + herbs group (A + H group); RIA was taken to measure the serum levels of PRL, P, E2. Results PRLR, PR mRNA expression in decidue of Group A was significantly lower than the A + H group (P<0. 01) , no difference in ER mRNA expression (P>0. 05); the abortion rate of Group A was 67 %, Group A+H was 17% , the difference was significant; as for the PRL and P level of day 7-1.0, the A group was significantly lower than the A+H group (P<0. 05).Conclusion Bromocriptine could induce abortion by declining the blood PRL, P level and downregulating PRLR, PR mRNA expression in decidue. Chinese herbs might maintain pregnancy by promoting PRL, P secretion and upregulating PRLR, PR mRNA expression in decidue.

补肾益气清热方对溴隐亭致大鼠流产模型中垂体PRL-R、PrRP-R表达的影响

目的 :探讨补肾益气清热中药对溴隐亭致 SD大鼠流产模型中垂体 PRL- R、Pr RP- R表达的影响。方法 :将 SD孕大鼠随机分 5组 :其中 A～ D组在孕 6～ 8d皮下注射溴隐亭 0 .3mg/( kg· d) ,A组为模型组 ,B组、C组、D组孕 1～ 1 1 d分别灌胃中药粉剂 3g/( kg· d)、注射外源性 PRL 8IU/次 (每天 1 2 :0 0和 2 4 :0 0 ,bid)、黄体酮 8mg/( kg·d) ;E组为正常妊娠组。所有动物于孕 1 2 d处死 ,取垂体 ,用 RT- PCR方法测各组大鼠垂体 Pr RP- R、PRL- R的表达。结果 :B组、C组、D组的妊娠率与 A组相比 ,差异有显著性 ( P<0 .0 1 ) ,B组妊娠率与 C组、D组、E组相比差异无显著性。 A组垂体 Pr RP- R、PRL- R的表达明显高于其它各组 ( P<0 .0 5 )。结论 :补肾益气清热中药可能通过机体的整体调节并作用于下丘脑、垂体 ,影响

乳腺癌PRL-R表达阳性随年龄变化规律探究

目的 探讨乳腺癌原发灶PRL-R表达阳性随年龄变化的规律。方法 收集中山大学肿瘤防治中心行手术治疗的129例乳腺癌患者,中位年龄46岁。采用免疫组化法配合单克隆抗体检测各病例术后原发灶标本蜡块中PRL-R的表达状况,并分析PRL-R表达阳性随患者年龄的变化规律。结果 129例患者中PRL-R阳性表达88例,阳性率68.2%。以每5岁作亚单元计算PRL-R阳性率的结果显示出35岁和55岁两个重要变化节点,以此两个年龄节点将129例患者分成年龄递进三个亚组,Spearsman秩相关分析显示出PRL-R表达阳性与年龄增长总体呈负相关（r=-0.183,P〈0.05）,且36~55岁组患者PRL-R阳性率高于〉55岁组患者（2=8.016,P=0.005）。结论 总体上PRL-R表达阳性与患者年龄增长呈负相关,其变化规律大致为：35岁后PRL-R表达阳性率可见增高趋势,然后于55岁左右又快速降至较低水平。

开郁醒神法对高催乳素血症患者卵巢动脉血流参数的影响

目的:观察开郁醒神法治疗高催乳素血症的临床疗效。方法:将60例肝郁肾虚型高催乳素血症患者随机分为对照组和观察组,每组30例。对照组采用甲磺酸溴隐亭片治疗,观察组给予开郁醒神法中药治疗。比较两组患者治疗前后的血清泌乳素(Prolactin,PRL)、促卵泡生成素(Follicle-stimulating Hormone,FSH)、黄体生成素(Luteinizing Hormone,LH)、雌二醇、孕酮、睾酮,以及卵巢的血管化指数(Vascularization Index,VI)、血流指数(Flow Index,FI)和血管化血流指数(Vascularization Flow Index,VFI)等指标,并比较中医证候评分,评价疗效。结果:治疗后,两组患者的PRL水平均明显下降(P<0.05),且观察组改善优于对照组(P<0.05)。治疗后,对照组患者的FSH、LH、雌二醇、孕酮和睾酮水平无明显变化(P>0.05),观察组患者FSH、LH水平明显下降,雌二醇水平显著升高(P<0.05),且观察组改善优于对照组(P<0.05)。观察组孕酮和睾酮水平无明显变化(P>0.05)。治疗后,对照组患者卵巢VI、FI和VFI水平无明显变化(P>0.05),观察组患者卵巢VI、FI和VFI水平均显著升高(P<0.05),且升高优于对照组(P<0.05)。治疗后,对照组中医证候评分水平略有下降,但组内差异无统计学意义(P>0.05);观察组中医证候评分水平显著下降(P<0.05),且下降优于对照组(P<0.05)。观察组总有效率高于对照组,组间差异有统计学意义(P<0.05)。结论:开郁醒神法中药可以显著降低高催乳术血症患者PRL、FSH和LH水平,纠正紊乱的垂体功能;提高雌二醇水平,恢复卵巢分泌功能;还可以显著提高卵巢动脉VI、FI和VFI水平,改善卵巢动脉血流灌注;并能显著降低中医证候评分水平,舒缓临床证候,显著提高治疗有效率。

3种流产剂对大鼠妊娠干预作用的比较研究

为研究米非司酮、溴隐亭和脂多糖3种流产剂对SD大鼠妊娠的影响。通过有无阴栓和阴道分泌物涂片确定SD大鼠是否妊娠,并将妊娠大鼠随机分为空白对照组、米非司酮组、溴隐亭组和脂多糖组。空白对照组于妊娠6~8 d皮下注射生理盐水,其余各组皮下注射相应流产剂,建立流产模型。于妊娠12 d观测各组流产率、血液生化指标,ELISA检测炎性细胞因子和孕激素水平,苏木精-伊红染色法(hematoxylin-eosin staining,HE)染色检测肝脏及子宫组织的病理学变化。结果显示,空白对照组、米非司酮组、溴隐亭组和脂多糖组的流产率分别为0、100%、50%和33.3%;与空白对照组相比,各流产剂致流产模型组大鼠子宫连胎重、孕激素水平均显著降低(P<0.05),TNF-α、IL-2、IL-12、IL-6、IL-1β水平均显著增加(P<0.05),且均会对肝、肾、子宫组织造成不同程度的代谢和病理性损伤;与空白对照组相比,各组核因子-κB(nuclear factor-kappa B,NF-κB)p65的表达更为强烈,雌激素受体(estrogen receptor,ER)表达水平降低。表明溴隐亭用于致流产的效果优于米非司酮和脂多糖,对母体损伤小。

甲磺酸溴隐亭自微乳的研制及其质量评价

目的制备甲磺酸溴隐亭自微乳制剂,并进行质量评价。方法通过饱和溶解度测定筛选油相、乳化剂、助乳化剂;通过配伍试验、绘制伪三元相图确定处方;再以粒径、载药量为指标,应用星点设计-响应曲面法优化处方;最后对自微乳的显微形态、自乳化时间、粒径和载药量的影响因素、溶出度、稳定性进行质量评价。结果最优处方三乙酸甘油酯21.33%,PEG 40氢化蓖麻油41.74%,PEG 40036.93%。经优处方制备的自微乳,显微形态为内相规整且分布均匀的球形,自乳化时间22.7 s,粒径为16.81 nm,载药量为19.79 mg·g^(-1),且并未因稀释倍数、温度和离心改变发生较大变化,溶出度有大幅度提高,在4、25℃和冷热循环系统下贮藏稳定。结论研制出的甲磺酸溴隐亭液体自微乳工艺较好,粒径分布均匀,载药量较高,体系稳定。

甲磺酸溴隐亭联合人绒毛膜促性腺激素治疗高泌乳素血症的临床效果及对激素水平的影响

目的 观察甲磺酸溴隐亭联合人绒毛膜促性腺激素治疗高泌乳素血症的临床效果及对患者激素水平的影响。方法 将2022年1月至2023年9月武义县第一人民医院妇产科收治的144例高泌乳素血症患者以随机数字表法分为观察组、对照组,每组72例,对照组口服甲磺酸溴隐亭片治疗,观察组患者口服甲磺酸溴隐亭片治疗的同时联合人绒毛膜促性腺激素治疗,比较两组临床疗效、治疗前后血清泌乳素及黄体生成激素、雌二醇等激素水平变化、女性性功能指数(FSFI)及贝克忧郁量表第2版(BDI-Ⅱ)评分变化、患者停药3个月与6个月后疾病复发率情况以及不良反应发生情况。结果 对照组与观察组总有效率分别为86.11%、97.22%,差异有统计学意义(χ^(2)=4.455,P<0.05);治疗后,观察组血清泌乳素为(24.38±5.52)μg·L^(-1),低于对照组(28.65±4.92)μg·L^(-1),黄体生成激素、雌二醇等激素水平分别为(20.99±2.15) pg·m L^(-1)、(53.84±7.23) IU·L^(-1),均高于对照组(18.54±2.55) pg·m L^(-1)、(49.63±8.23) IU·L^(-1),差异有统计学意义(t=4.900、6.233、3.261,均P<0.001);观察组治疗后FSFI评分为(32.12±1.85)分,高于对照组(28.54±3.25)分,BDI-Ⅱ评分为(8.76±0.62)分,低于对照组(10.34±0.85)分,差异有统计学意义(t=8.123、12.743,均P<0.001);对照组(4.17%)与观察组(2.78%)患者不良反应发生率相近,差异无统计学意义(χ^(2)=0.000,P>0.05);对照组停药3个月疾病复发率为5.56%,高于观察组(0),但差异无统计学意义(χ^(2)=2.314,P>0.05);对照组停药6个月疾病复发率为8.33%,高于观察组(0),差异有统计学意义(χ^(2)=4.348,P<0.05)。结论 甲磺酸溴隐亭与人绒毛膜促性腺激素联合治疗高泌乳素血症临床效果显著,可改善患者激素水平及性功能、不良心理,且停药后患者疾病复发率低,不良反应少。

基于症状改善及实验室检测评价乳痈消方治疗肿块期非哺乳期乳腺炎的研究

目的研究乳痈消方治疗肿块期非哺乳期乳腺炎(NPM)对患者症状和实验室检测指标的改善效果。方法以2020年8月—2022年4月浙江中医药大学附属丽水中医院收治的88例肿块期NPM患者随机分为西药组(44例)和联合中药组(44例)。西药组采用甲磺酸溴隐亭进行治疗,联合中药组在西药组的基础上采用乳痈消方进行治疗,两组均治疗4周。统计两组治疗4周后的疗效,比较两组治疗前和治疗4周后症状体征积分、实验室检测指标、炎症指标。结果治疗4周后,联合中药组总有效率高于西药组(P<0.05)。治疗4周后与治疗前比较,两组乳房脓肿、乳房肿物、乳房瘘管、乳房红肿、乳房疼痛、乳头凹陷评分及血清免疫球蛋白A(IgA)、总补体(TC)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、外周血白细胞(WBC)、中性粒细胞(N)、自然杀伤细胞(NK)水平降低,联合中药组乳房脓肿、乳房肿物、乳房瘘管、乳房红肿、乳房疼痛、乳头凹陷评分及血清TC、IL-6、TNF-α、CRP、外周血WBC、N、NK水平低于西药组(P<0.05)。治疗4周后与治疗前比较,两组外周血CD_(4)^(+)水平升高,联合中药组高于西药组(P<0.05)。结论乳痈消方治疗肿块期NPM,可有效改善患者症状及实验室指标,调节机体免疫功能,降低机体炎症反应,具有较好的治疗效果。

降乳方联合溴隐亭治疗特发性高催乳素血症月经后期临床研究

目的研究降乳方联合溴隐亭对特发性高催乳素(prolactin,PRL)血症月经后期的疗效。方法将60例特发性高PRL血症月经后期患者随机分为治疗组(30例)和对照组(30例),治疗组给予降乳方加溴隐亭,对照组给予溴隐亭,比较两组治疗后的血清PRL、雌二醇(estradiol,E2)、卵泡刺激素(follicle-stimulating hormone,FSH)、黄体生成素(luteinizing hormone,LH)水平,月经积分,中医证候积分,基础体温(basal body temperature,BBT),疗效,用药不良反应及停药后复发率。结果治疗后,两组血清PRL水平均降低,E2、FSH、LH水平及BBT双向率均升高,差异有统计学意义(P<0.01);且治疗组月经积分及中医证候积分均低于对照组,差异有统计学意义(P<0.01);治疗组中医证候疗效总有效率96.67%高于对照组的80%,总体疗效的有效率96.67%高于对照组的73.33%,差异均具有统计学意义(P<0.05);治疗组不良反应发生率为6.67%,低于对照组的26.67%,且治疗组复发率为6.67%,低于对照组的37.04%,差异均具有统计学意义(P<0.05)。结论降乳方联合溴隐亭可使高PRL血症月经后期患者体内PRL水平降低,使E2、FSH、LH水平升高,使中医证候积分降低,调整月经周期,提高排卵率,提高临床疗效,用药安全性高,停药后复发率低。

中药对溴隐亭致流产大鼠保胎机理的实验研究

目的 :探讨补肾益气中药对流产大鼠保胎的作用及其机理。方法 :采用孕 6、7、8d皮下注射溴隐亭 0 12 5mg d ,诱发SD大鼠流产模型 ,以放免法测血清PRL、P的动态变化 ;RT PCR法测孕 12d蜕膜Th1 Th2型细胞因子的表达 ,观察中药治疗对妊娠结局及以上指标的影响。结果 :溴隐亭致流产模型血清PRL、P水平下降 ,母胎界面Th1 Th2型细胞因子平衡偏向Th1型 ,补肾益气中药可使其血清PRL及P水平升高 ,母胎界面Th1 Th2型细胞因子平衡恢复正常。结论 :改良溴隐亭致流产模型具备免疫内分泌网络失调的特征 ,中药可通过对母胎界面免疫内分泌网络的调控维持妊娠。